tailieunhanh - Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting

The TROIKA trial established that HD201 and trastuzumab were equivalent in terms of primary end-points (total pathological complete response) following neoadjuvant treatment. The objective of the present analysis was to compare survival outcomes and final safety. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN